We are live on
!
Find out more
ACM
Altium Capital Management Portfolio holdings
AUM
$42M
This Fund
S&P 500
This Quarter
Est. Return
+8.33%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$180M
AUM Growth
-$16.6M
(-8.5%)
Cap. Flow
-$8.49M
Cap. Flow
% of AUM
-4.71%
Top 10 Holdings %
Top 10 Hldgs %
42.71%
Holding
128
New
34
Increased
5
Reduced
15
Closed
37
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AVDL
Avadel Pharmaceuticals
AVDL
|
+$4.11M |
| 2 |
Penumbra
PEN
|
+$4.08M |
| 3 |
Alphatec Holdings
ATEC
|
+$3.82M |
| 4 |
Inspire Medical Systems
INSP
|
+$3.16M |
| 5 |
Varex Imaging
VREX
|
+$3.14M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AKRO
Akero Therapeutics
AKRO
|
+$6.85M |
| 2 |
PEPL
PepperLime Health Acquisition Corporation Class A Ordinary Share
PEPL
|
+$6.47M |
| 3 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
+$5.29M |
| 4 |
Rhythm Pharmaceuticals
RYTM
|
+$4.95M |
| 5 |
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
|
+$4.32M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 85.22% |
| 2 | Financials | 3.64% |
| 3 | Technology | 0.85% |
| 4 | Communication Services | 0.51% |
| 5 | Materials | 0.17% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ATXS
1
DELISTED
Astria Therapeutics
ATXS
| $17.9M | 9.95% |
1,347,088
-8,284
| -0.6% | -$112K |
|
2
CALL
NovoCure
NVCR
$1.89B
| $9.71M | 5.39% |
+161,500
| New | +$12.9M |
|
3
ADMA Biologics
ADMA
$2.04B
| $9.5M | 5.27% |
2,870,000
| – | – |
|
|
BLU
4
DELISTED
BELLUS Health Inc.
BLU
| $8.15M | 4.52% |
1,132,000
| – | – |
|
|
KDNY
5
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $7.06M | 3.92% |
305,000
-80,000
| -21% | -$1.91M |
|
6
Amylyx Pharmaceuticals
AMLX
$2.17B
| $5.43M | 3.01% |
185,000
+45,000
| +32% | +$1.56M |
|
|
CBAY
7
DELISTED
Cymabay Therapeutics
CBAY
| $5.41M | 3% |
620,000
-405,000
| -40% | -$3.24M |
|
|
ACLX
8
DELISTED
Arcellx
ACLX
| $4.62M | 2.57% |
150,000
| – | – |
|
|
AVDL
9
DELISTED
Avadel Pharmaceuticals
AVDL
| $4.58M | 2.54% |
+500,000
| New | +$4.11M |
|
10
Glaukos
GKOS
$8.89B
| $4.56M | 2.53% |
91,000
| – | – |
|
|
11
Penumbra
PEN
$12.6B
| $4.46M | 2.48% |
+16,000
| New | +$4.08M |
|
|
12
Alphatec Holdings
ATEC
$1.43B
| $4.21M | 2.34% |
+270,000
| New | +$3.82M |
|
13
Myriad Genetics
MYGN
$502M
| $4.18M | 2.32% |
180,000
-32,000
| -15% | -$650K |
|
14
NeoGenomics
NEO
$1.74B
| $4.18M | 2.32% |
240,000
-45,000
| -16% | -$641K |
|
|
AKYA
15
DELISTED
Akoya BioSciences
AKYA
| $4.09M | 2.27% |
500,000
+170,000
| +52% | +$1.78M |
|
16
Xtant Medical Holdings
XTNT
$59.7M
| $3.97M | 2.2% |
6,227,559
-18,732
| -0.3% | -$13.7K |
|
17
ResMed
RMD
$30.3B
| $3.72M | 2.07% |
17,000
| – | – |
|
|
CTIC
18
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
| $3.57M | 1.98% |
850,000
+400,000
| +89% | +$2.08M |
|
19
Biohaven
BHVN
$2.07B
| $3.55M | 1.97% |
260,000
+60,000
| +30% | +$955K |
|
|
RETA
20
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $3.18M | 1.77% |
+35,000
| New | +$2.05M |
|
|
ISEE
21
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $3.16M | 1.76% |
130,000
-60,000
| -32% | -$1.31M |
|
|
MRSN
22
CALL
DELISTED
Mersana Therapeutics
MRSN
| $3.08M | 1.71% |
+30,004
| New | +$4.21M |
|
|
23
Varex Imaging
VREX
$469M
| $3M | 1.67% |
+165,000
| New | +$3.14M |
|
|
24
Inspire Medical Systems
INSP
$1.5B
| $2.93M | 1.62% |
+12,500
| New | +$3.16M |
|
25
KORU Medical Systems
KRMD
$184M
| $2.89M | 1.6% |
685,002
-169,998
| -20% | -$669K |
|
Similar funds
TA
SIM
LSA
VEPM
GC
VI
BCM
VAM
Altium Capital Management's Q1 2023 Portfolio in Review
As of Q1 2023, Altium Capital Management held 128 positions worth $180M, down 8.5% from $197M the previous quarter. Its ten largest holdings account for 43% of the portfolio.
Altium Capital Management withdrew a net $8.49M in Q1 2023, closing 37 positions and reducing 15 holdings. Its most notable exit was Akero Therapeutics, an estimated $6.85M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 85% of assets, down from 89% a quarter earlier, followed by Financials and Technology.
Against the trend, Altium Capital Management opened a new position in Avadel Pharmaceuticals worth $4.58M.
- Altium Capital Management's largest Q1 2023 buy was Avadel Pharmaceuticals: 500,000 shares worth $4.58M.
- Altium Capital Management added most to CTI BioPharma Corp. (DE) Common Stock in Q1 2023, an estimated $2.08M increase.
- Altium Capital Management's biggest Q1 2023 reduction was PepperLime Health Acquisition Corporation Class A Ordinary Share, cutting an estimated $6.47M.
- Altium Capital Management fully exited Akero Therapeutics in Q1 2023, selling an estimated $6.85M.
- Altium Capital Management's ten largest holdings make up 43% of its $180M portfolio in Q1 2023.
- Altium Capital Management opened 34 new positions and closed 37 in Q1 2023.
- Altium Capital Management's portfolio value fell 8.5% quarter-over-quarter to $180M.
Based on Altium Capital Management's 13F filing for Q1 2023, filed 15 May 2023.